증권사 리포트&코멘트
ADEL Signs $1.04 Billion Global License Agreement with Sanofi for ADEL-Y01, a Novel inves…
prnewswire.com
ADEL Signs $1.04 Billion Global License Agreement with Sanofi for ADEL-Y01, a Novel investigational Alzheimer's Disease Therapy
/PRNewswire/ -- ADEL, Inc., a biopharmaceutical company dedicated to developing therapies for neurodegenerative diseases such as Alzheimer's Disease, today...
외부 자료를 정리한 참고자료이며 투자 권유가 아닙니다. 기사·리포트의 저작권은 원저작자에게 있습니다. · 게시중단 요청